MedTrace Logo

The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

NCT02459977 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-06-02

No results posted yet for this study

Summary

Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Basiliximab

Basiliximab induction therapy

DRUG

No basiliximab

No basiliximab induction therapy

PROCEDURE

Kidney transplantation

kidney transplantation

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Su-Kil Park, M.D, PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459977 on ClinicalTrials.gov